Overview

Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to use Sorafenib plus Docetaxel to evaluate pharmacodynamics (PD) in Patients with prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Italian Trial in Medical Oncology
Treatments:
Docetaxel
Niacinamide
Sorafenib